消息面上，相关机构近期表示，创新药仍处于产业加速向上的周期，今年也有强基本面的兑现支撑。在 既往ADC、PD1/VEGF等技术爆发之后，TCE、ProTac等新技术已经看到萌芽开花；同时，创新药从可 预期的BD潮走向盈利潮，以往大家对创新药的疑虑是研究壁垒高、企业没盈利，因此不敢投，但随着 未来企业的收入高增速带动利润的快速提升，就进入了投资者可理解的范畴内。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，4月24日最新市盈率仅为 27倍，不足两个月前的一半，当前布局性价比突出。 4月24日，港股市场低开震荡，港股创新药板块全面爆发。港股创新药指数成分股中，凯莱英涨超 17%，荣昌生物、亚盛医药-B、康方生物涨超7%，信达生物、联邦制药涨超6%，康龙化成、三生制药 涨超4%。港股创新药ETF（159567）连续2个交易日成交额超9亿元，市场关注度较高。 西南证券表示，创新药板块的投资价值在于其背后的新质生产力和高质量发展的大背景。随着各地政府 不断出台支持创新药的政策，如北京、深圳等地发布的支持创新药政策，这些政策不仅加强了对创新药 械研发、生产、审批、使用的全链条支持，还促进了健 ...

Group 1: Market Performance - The Hang Seng Biotechnology Index (HSHKBIO) rose by 2.65% as of April 24, 2025, with notable increases in constituent stocks such as Rongchang Biopharmaceutical (09995) up 11.47%, Ascentage Pharma-B (06855) up 8.46%, and Innovent Biologics (01801) up 7.68% [1] - The Hang Seng Biotechnology ETF (513280) also increased by 2.62%, marking its fifth consecutive rise, with the latest price at 0.9 HKD [1] - Over the past week, the Hang Seng Biotechnology ETF has accumulated an 8.79% increase, ranking in the top third among comparable funds [1] - The ETF's liquidity was strong, with a turnover rate of 13.76% and a trading volume of 36.43 million HKD, indicating active market participation [1] - In the past month, the ETF's average daily trading volume was 82.80 million HKD, and it saw a significant increase of 7 million shares in the last month, placing it in the top third of comparable funds [1] Group 2: Company Developments - On April 23, 2025, CanSino Biologics announced that its bispecific antibody drug, Ivorisumab, successfully outperformed PD-1 in a head-to-head trial against BeiGene's Tislelizumab for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) [4] - The trial results were described as having strong positive outcomes, with statistical significance and major clinical benefits, leading to a surge in CanSino's stock price, which rose over 10% to reach a historical high of 100 HKD per share [4] - The National Medical Products Administration (NMPA) has proposed a six-year data protection period for innovative drug trial data, which is seen as a significant encouragement for drug research and development [4] Group 3: Industry Insights - Guosen Securities highlighted the importance of focusing on innovative drugs that are accelerating their international presence and benefiting from policy support [5] - Since the beginning of 2025, domestic innovative drug companies have completed numerous outbound licensing transactions, indicating a growing global competitive edge in research and clinical data [5] - The upstream pharmaceutical research and development sector is viewed as a critical component of China's self-sufficient industrial chain, with opportunities for quality companies to accelerate growth amid tariff impacts from the U.S. [5] Group 4: ETF Characteristics - The Hang Seng Biotechnology ETF (513280) is noted for having the lowest fees in the market for Hong Kong innovative drug products, with a management fee of only 0.15% per year and a custody fee of 0.05% per year, significantly lower than similar products [6] - As of December 2024, the ETF's index composition includes 66.4% innovative drugs, 15.4% CXO, and over 9% in pharmaceutical distribution and medical devices, indicating a balanced exposure across sectors [6]

Group 1 - In the first quarter of 2025, 25 new stocks were listed in the US market, raising a total of $667.1 million, while 17 new stocks were listed in the Hong Kong market, raising a total of HKD 17.169 billion [1][10] - The number of Chinese companies listed in the US increased by 79% compared to the same period in 2024, with 24 IPOs and 1 SPAC, despite a decrease in total fundraising compared to the previous year [2][19] - The highest fundraising amounts were achieved by Smithfield and Ascent Pharma, raising $260 million and $126 million respectively, accounting for 64% of the total fundraising [2][4] Group 2 - In the US market, the average fundraising amount for Chinese companies was $24.27 million, with 72% of companies raising less than $10 million [4] - The pharmaceutical and biotechnology sector had the highest number of listings, with 5 companies, while the consumer sector accounted for 43.7% of total fundraising [6][16] - The first quarter of 2025 saw a diverse range of industries represented, including emerging fields such as integrated smart parking solutions and creative design platforms [6] Group 3 - In the Hong Kong market, the total fundraising amount increased by 363% compared to the previous year, with 15 IPOs and 1 SPAC [10][13] - The top three companies in Hong Kong (Mixue Ice City, Chifeng Gold, and Nanshan Aluminum) raised a combined total of HKD 8.628 billion, accounting for 50.2% of the total fundraising [13] - The beverage and biopharmaceutical sectors emerged as popular areas for investment, with significant fundraising contributions from leading companies [16] Group 4 - The Hong Kong market exhibited a dual characteristic of industry concentration and regional differentiation, with emerging sectors like beverage and biopharmaceuticals showing strong fundraising capabilities [16] - Traditional manufacturing remains dominant, accounting for 41.2% of listings, with resource-based industries like gold mining and alumina production performing particularly well [16] - The geographical distribution of listed companies showed that the Yangtze River Delta region contributed significantly to both the number of listings and total fundraising [16]

Core Insights - Ascentage Pharma announced the selection of results from two clinical studies of its drug candidates, lisaftoclax (APG-2575) and alrizomadlin (APG-115), for presentation at the 2025 ASCO Annual Meeting [1][3] - The ASCO Annual Meeting is a significant event in the oncology field, attracting over 40,000 professionals globally [2] - The company aims to advance its clinical development and provide more treatment options for patients with hematological malignancies [3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on therapies for unmet medical needs, particularly in hematological malignancies [1][7] - The company has been listed on the Hong Kong Stock Exchange since October 2019 and on the Nasdaq since January 2025 [8] - Ascentage Pharma has a diverse pipeline of innovative drug candidates targeting key proteins in the apoptotic pathway and next-generation TKIs [9] Clinical Studies - A Phase 1b/2 study of lisaftoclax combined with azacitidine in patients with treatment-naïve or prior venetoclax-exposed myeloid malignancies will be presented [4] - A Phase 2 study of alrizomadlin with or without toripalimab in patients with advanced adenoid cystic carcinoma or other solid tumors will also be presented [5] Regulatory Status - Lisaftoclax and alrizomadlin are investigational drugs and are not yet approved in the U.S. [6] - Olverembatinib, another key asset, is approved in China and included in the National Reimbursement Drug List [10] - The company has received multiple Orphan Drug Designations from the US FDA and the European Medicines Agency for its investigational drug candidates [11] Partnerships and Collaborations - Ascentage Pharma has established partnerships with leading biotechnology and pharmaceutical companies, including Takeda, Merck, and Pfizer, as well as research institutions like Mayo Clinic and Dana-Farber Cancer Institute [11]

Core Insights - Ascentage Pharma's novel drugs, lisaftoclax (APG-2575) and olverembatinib, have been included in the 2025 CSCO Guidelines, marking significant advancements in the treatment of hematological malignancies [1][9] Group 1: Lisaftoclax (APG-2575) - Lisaftoclax (APG-2575) is the first China-developed Bcl-2 inhibitor to receive a recommendation in the CSCO Guidelines for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2][3] - The drug has shown a high overall response rate and a favorable tolerability profile, with a lower incidence of tumor-lysis syndrome compared to other Bcl-2 inhibitors [3] - Lisaftoclax (APG-2575) is currently undergoing two registrational Phase III studies to broaden its treatment applications [3] Group 2: Olverembatinib - Olverembatinib has received an upgraded Level I recommendation in the CSCO Guidelines for treating children with Ph+ acute lymphoblastic leukemia (ALL) who have the T315I BCR-ABL1 mutation [4][5] - The drug retains Level I recommendations for chronic myeloid leukemia (CML) treatment across various phases and mutations, emphasizing its role in addressing multiple BCR::ABL1 mutations [6][7] - Olverembatinib is recognized as a major breakthrough in pediatric hematology and is included in the China National Reimbursement Drug List, enhancing patient accessibility [8][12] Group 3: Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on developing therapies for hematological malignancies and has been listed on both the Hong Kong Stock Exchange and Nasdaq [10][12] - The company has a diverse pipeline of innovative drug candidates targeting key proteins involved in cancer treatment, including Bcl-2 and MDM2-p53 inhibitors [11] - Ascentage Pharma aims to strengthen its R&D capabilities and accelerate clinical development to meet unmet medical needs globally [15]

R&D Investment and Clinical Trials - Ascentage Pharma reported a significant increase in R&D investment, totaling approximately $50 million, representing a 25% increase year-over-year[2]. - The company is advancing multiple clinical trials, with APG-2575 showing promising results in Phase II trials for chronic lymphocytic leukemia (CLL)[1]. - Ascentage Pharma is focusing on the development of its novel small molecule drugs, with five candidates currently in various stages of clinical trials[1]. - The company has received breakthrough therapy designation (BTD) for APG-115, which is expected to expedite its development process[2]. - The company is conducting ten registration clinical studies, with two approved by the FDA, involving Olverembatin, Lisaftoclax (APG-2575), and APG-2449[25]. - The company is conducting multiple registration trials for CLL/SLL, AML, and MDS, with ongoing phase II trials for multiple myeloma (MM)[34]. - The company is actively recruiting patients for multiple clinical trials of Alrizomadlin (APG-115) in the U.S. and Australia[51]. - Lisaftoclax is undergoing multiple clinical trials in both China and the U.S. for various hematological malignancies[47]. - The company has initiated patient recruitment for the POLARIS-2 and POLARIS-3 registration clinical trials following FDA approval in February 2024[41]. - The company is focused on accelerating the development and launch of innovative therapies that can change patient lives, aiming to expand its global influence[26]. Financial Performance - Ascentage Pharma's revenue for the fiscal year reached $100 million, a 15% increase compared to the previous year[2]. - The company anticipates a revenue guidance of $120 million for the next fiscal year, reflecting a growth rate of 20%[2]. - The company reported a significant increase in user data, with a 25% growth in patient enrollment for clinical trials compared to the previous year[10]. - Total revenue for 2023 reached RMB 221,984 thousand, a 5.5% increase from RMB 209,711 thousand in 2022[22]. - The company projects a revenue target of RMB 980,650 thousand for 2024, representing a substantial growth of 341.5% compared to 2023[22]. - The company's revenue for the year ended December 31, 2024, was RMB 980.7 million, a significant increase of RMB 758.7 million or 342% compared to RMB 222.0 million for the year ended December 31, 2023[81]. - The total comprehensive loss for the year ended December 31, 2024, was RMB 398.7 million, down from RMB 899.5 million for the year ended December 31, 2023, representing a reduction of RMB 500.8 million or 55.6%[81]. - The company recorded a loss of RMB 405.7 million for the year ended December 31, 2024, a decrease of RMB 520.0 million or 56.2% from RMB 925.7 million for the previous year[93]. Market Expansion and Strategic Partnerships - Ascentage Pharma plans to expand its market presence in Europe and North America, targeting a 30% increase in market share by 2025[2]. - The company has initiated a strategic partnership with a leading pharmaceutical firm to co-develop new oncology therapies, aiming to accelerate product development timelines[2]. - A new partnership with a leading pharmaceutical company is expected to enhance distribution channels, potentially increasing sales by 40%[10]. - The company is exploring potential acquisitions to enhance its pipeline and strengthen its competitive position in the oncology market[2]. - The company has established strategic collaborations with leading biotech and pharmaceutical companies, including Incyte and AstraZeneca, enhancing its research and development capabilities[33]. Product Pipeline and Approvals - The core product HQP1351 is designed to overcome drug resistance caused by BCR-ABL kinase mutations, specifically targeting the T315I mutation[9]. - HQP1351 has been approved for all indications in China and included in the national medical insurance catalog since January 2025, enhancing affordability and accessibility for patients[35]. - The NDA for the new Bcl-2 selective inhibitor Lisaftoclax (APG-2575) was accepted by the CDE in November 2024 and is under priority review for treating relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)[24]. - Lisaftoclax has been granted orphan drug designation by the FDA for five indications, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML)[43]. - The company plans to launch Alrizomadlin (APG-115) for relapsed/refractory CLL/SLL in China by 2025, pending regulatory approval[51]. - The company has received FDA approval for clinical trials in the U.S. for multiple indications, including CML and GIST[37]. Intellectual Property and Technology - The company has a strong intellectual property portfolio with 541 authorized patents globally, of which 379 are licensed overseas[33]. - The company is leveraging advanced technologies in drug development to address unmet medical needs in cancer treatment[31]. - The company is developing targeted protein degraders to address resistance mechanisms in cancer therapies, with the first candidate aimed at the p53-MDM2 pathway[67]. Workforce and Management - The company plans to increase its workforce by 20% to support expanded operations and R&D efforts[11]. - As of December 31, 2024, the company has 567 full-time employees, with 71.8% (407 employees) in R&D, 16.4% (93 employees) in commercial roles, and 11.8% (67 employees) in administrative functions[114]. - The senior management team consists of 187 senior employees with an average of 15 to 20 years of experience in the biotechnology industry[114]. - The company actively recruits talent globally by providing a collaborative work environment, competitive compensation, and opportunities to engage in cutting-edge scientific projects[114]. Financial Risks and Challenges - The company reported a significant net loss during the reporting period, indicating challenges in achieving or maintaining profitability despite the commercialization of Nairik® (Orebatin) in China[174]. - The company requires additional financing to support operations, and failure to secure such financing may hinder the development and commercialization of candidate drugs, including Nairik® (Orebatin)[174]. - The company faces significant competition, which may lead to others discovering, developing, or commercializing competitive drugs ahead of it[178]. - The company has identified significant deficiencies in internal controls over financial reporting, which may impact the accuracy of financial performance reporting[188]. - The company relies on third parties for clinical trials and manufacturing, which poses risks if these parties fail to meet their obligations[1]. Corporate Governance and Social Responsibility - The company is committed to environmental responsibility and sustainable development, adhering to relevant laws and regulations[171]. - The company made charitable donations totaling RMB 4.3 million to various foundations[196]. - The company emphasizes the importance of maintaining good relationships with employees, customers, and suppliers to achieve business objectives[167].

Group 1 - The core viewpoint of the article highlights the uncertainty in the economic situation due to multiple policy adjustments, leading to a cooling trend in both primary and secondary markets in the US stock market during Q1 2025 [1] - The Dow Jones Industrial Average fell by 1.28%, the Nasdaq index dropped by 10.42%, and the S&P 500 index decreased by 4.59% in Q1 2025 [1] - The total amount raised through equity financing in Q1 2025 was $44.4 billion, a decrease of 11.80% compared to $50.3 billion in the same period last year [1][4] Group 2 - In Q1 2025, there were 88 successful IPOs, an increase of 36 compared to the same period last year, with a total financing amount of $11.4 billion, up 18.21% year-on-year [1][16] - The largest IPO was by Venture Global, raising $1.75 billion [31] - SPAC IPOs saw 19 companies listed, an increase of 11 from the previous year, raising $2.6 billion, which is a 57.45% increase [34] Group 3 - The refinancing events in Q1 2025 totaled 209, a decrease of 35 from the previous year, with a total amount of $33 billion, down 18.93% [1][39] - The non-bank financial sector led in refinancing amounts with $16.2 billion, followed by the oil and petrochemical sector at $4.9 billion [10][45] - The top refinancing project was Charles Schwab, raising $13.111 billion [50] Group 4 - Goldman Sachs led the IPO underwriting rankings with an underwriting amount of $1.431 billion from 8 deals [2][53] - TD Securities topped the refinancing underwriting scale with $8.289 billion from 10 deals [57] - The most active refinancing underwriter was H.C. Wainwright, participating in 27 events [58]

Investment Rating - The report maintains an "Outperform" rating for Ascentage Pharma [2][21]. Core Insights - Ascentage Pharma achieved a revenue of RMB 980 million in 2024, representing a year-on-year growth of 343%, which includes a $100 million option payment from Takeda. The company reported a net loss of RMB 410 million, narrowing by 56.2% year-on-year [3][17]. - The domestic revenue performance of HQP1351 was strong, reaching RMB 240 million, with a significant increase in H2 revenue driven by improved penetration in pharmacies and hospitals [4][18]. - The company completed its U.S. IPO in 2025, raising RMB 967 million, which alleviated cash needs [3][20]. Financial Summary - Revenue projections for FY25-27 are RMB 5.7 billion, RMB 29.9 billion, and RMB 28.0 billion, respectively. Corresponding net profits are projected at RMB -8.4 billion, RMB 12.5 billion, and RMB 9.1 billion [8][21]. - The gross profit margin is expected to remain high, with estimates of 90.1% in FY25 and 98.1% in FY26 [8][14]. - The company’s cash and deposit balance was RMB 1.26 billion at the end of 2024, reflecting a 15.3% increase year-on-year [3][17]. R&D Progress - Ongoing Phase III trials include POLARIS-2 for pretreated CML-CP and POLARIS-3 for SDH-GIST, with plans to submit a Phase III application to the U.S. FDA for POLARIS-1 [5][23]. - The NDA for APG-2575 for R/R CLL/SLL has been accepted by the CDE, with multiple Phase III trials ongoing for various indications [5][23]. Valuation - The target price for Ascentage Pharma is set at HKD 53.1 per share, based on a risk-adjusted discounted cash flow (DCF) model with a WACC of 10.0% and a terminal growth rate of 3.0% [8][21].

Core Viewpoint - In 2024, the Hong Kong pharmaceutical sector experienced significant declines due to external factors, with the Hang Seng Healthcare Index down 18.93% and the Hong Kong Innovative Drug Index down 10.80%. However, Ascentage Pharma-B (06855) saw a remarkable stock price increase of 66.48%, outperforming the indices due to multiple unexpected positive developments in product internationalization, innovative research, and secondary market financing, validating the company's "investment certainty" [1]. Financial Performance - Ascentage Pharma reported a revenue of RMB 981 million in 2024, a substantial increase of 342% year-on-year. The sales revenue of the core product, Nairik (耐立克®), reached RMB 241 million, reflecting a growth of approximately 53%. The company's cash flow improved, with a monetary fund balance of RMB 1.261 billion as of December 31, 2024, up 15.3% year-on-year [2]. Product Development and Market Potential - Nairik has successfully passed the 2024 National Medical Insurance negotiation process and will be included in the new National Medical Insurance Drug List starting January 1, 2025. This inclusion indicates strong recognition of the drug's innovative capabilities by the domestic medical system, which typically leads to rapid sales growth for innovative drugs post-inclusion [2]. - Ascentage Pharma signed a $1.3 billion exclusive option agreement with Takeda Pharmaceutical for Nairik, setting a new record for domestic small molecule oncology drug business development transactions [3]. Clinical Advancements - Nairik is positioned to become the first TKI drug approved for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, with significant market potential. The drug has been included in the "Breakthrough Therapy Designation" list and is expected to generate considerable sales growth in the Ph+ ALL treatment market [4][5]. - In the solid tumor field, Nairik's Phase III clinical trial for treating SDH-deficient GIST patients has received approval, and the drug has shown excellent anti-tumor effects in various clinical presentations [4]. Research and Development - Ascentage Pharma's R&D investment reached RMB 947 million in 2024, supporting strong revenue growth and cash flow expectations. The company is conducting ten registration clinical trials, with two receiving FDA approval, laying a solid foundation for exploring the global differentiated innovative drug market [5]. - The company has two core products, Nairik and APG-2575, both with billion-dollar potential, alongside several other promising candidates in development. Ascentage holds 541 global patents, with 379 granted overseas, establishing a robust global intellectual property framework [5]. Market Position and Future Outlook - APG-2575, a Bcl-2 inhibitor, has been accepted for priority review by the NMPA for treating refractory or relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It is expected to become the second Bcl-2 inhibitor approved globally, with projected sales exceeding $2 billion [6][7]. - Ascentage Pharma successfully listed on the US stock market in 2024, raising approximately $126 million, enhancing its international financing channels. The company is well-positioned as a high-value biopharmaceutical investment in the US market [7]. Conclusion - With strong cash flow and an integrated innovation loop, Ascentage Pharma is accelerating its transition to a leading global biopharma through systematic competition in global R&D, overseas registration, and international commercialization [8].

Core Insights - The core viewpoint of the articles highlights the strong performance and growth potential of Ascentage Pharma, particularly driven by its key products, including Nairik and APG-2575, which are positioned to capture significant market opportunities in the oncology sector [1][2]. Group 1: Financial Performance - Ascentage Pharma reported a total revenue of 981 million RMB for the year 2024, representing a 342% year-on-year increase, primarily driven by product sales and external collaboration licensing revenue [1]. - The sales revenue for Nairik reached 241 million RMB, showing a robust year-on-year growth of 52% [1]. Group 2: Product Development and Regulatory Approvals - Nairik is set to be included in the National Medical Insurance Drug List in November 2024, which is expected to provide broader growth opportunities for the company [1]. - Ascentage Pharma is advancing Nairik in three ongoing Phase III clinical trials for various indications, including Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), with one trial approved by the FDA [1]. - The company has established a global rights collaboration with Takeda for Nairik, marking the largest external licensing deal in the domestic small molecule oncology drug sector to date [1]. - The NDA for APG-2575 was accepted by the CDE and is prioritized for review, targeting treatment for refractory/relapsed Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), positioning it as a potential second Bcl-2 inhibitor to market globally [2]. - APG-2575 is currently involved in four global Phase III clinical trials across multiple hematological cancer indications, with one trial also receiving FDA approval [2]. Group 3: Market Position and Future Outlook - The successful IPO on NASDAQ in January 2025 raised 967 million RMB, enhancing the company's financial position for future growth initiatives [3].